Jean-Paul Alves, BSc in Economy, Graduated from EM Lyon, joined Pegascy in 2020 as Chief Financial Officer. He was appointed COO of Pegascy in 2021 and became CEO in 2024.

He began his career as Consultant at E&Y and Arthur Andersen. In 2000, he joined Lagardere Services as International Finance and M&A Advisor to the Executive Management. Later, he became Financial Director at AOL France (Time Warner) then Group CFO (and executive committee member) of Viadeo leading its IPO in 2014 before joining Biom’Up, a French Biotech, to organize its IPO in 2017 as Group CFO. Jean-Paul has a broad knowledge of international M&A and Funding operations with almost 10 acquisitions (including transactions in China, India, different countries in Europe, Russia and North America). He has carried out more than 23 funding operations during his career, including 2 IPO’s.

Dr. Jean-Pierre ARMAND (MD, MSc) – Chairman

Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI). He was recently General Director of the Institut Claudius Regaud in Toulouse. After a position as research fellow in Columbia University New York, Dr Armand has joined Institut Claudius Regaud in Toulouse where he was the head of Medical oncology until 1984. In the next 23 years at Institut Gustave Roussy (IGR) in Paris, he was successively CEO of the Hospital IGR3, head of the Department of Medical oncology at IGR2 and CMO of IGR&D, Dept of Innovation and Development. He founded the IGR Phase I Unit (Ditep) in the early 80s.

He conducted the phase 1 trials of numerous drugs now used routinely, including classicals cytotoxics,topo2 inhibitors, Irinotecan, Oxaliplatin, Taxotere, Navelbine, Vinflunine, and more recently targeted therapies, Sutent, Sorafenib, Temsirolimus... His involvement was critical in the success of 3 drugs that had been previously discarded after failure in phase 1 (CPT11 (Irinotecan), Oxaliplatin and SU11248 (Sutent))

Dr Armand started working on early drug development (phase 1 and 2) of new anticancer agents. He is expert in breast, head & neck, and neuro-oncology. He (co)authored over 300 medical and scientific peer-reviewed articles and he is/was member of the Editorial Boards of Annals of Oncology, the European Journal of Cancer, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Research., CISCO journal.

He today focuses on new therapies for orphan treatment cancer diseases and personally invest into biotech in oncology.

Vincent Ribrag, MD PhD, is medical oncologist by training and is currently working at Institut Gustave Roussy as head of the Hematology department and head of the early drug development tumor board. He has developed and is still in charge of the hematology phase I track at the early drug department. He led more than 50 phase I trials during the last 10 years and started the cell-therapy phase II program in solid tumors with JP Armand. Among numerous experimental activities, he created a translational hematology laboratory and was associated with different INSERM research units the last years. He is currently affiliated to INSERM UMR-1170 led by Dr Olivier Bernard entitled “transcriptional control and epigenetics of malignant hematopoiesis”. He has been involved in over 550 publications and is member of several international cancer societies, namely the American Association of clinical Oncology (ASCO) and the American Society of Hematology (ASH). He is included in the Scientific and Administrative Committees of LYSA network and CALYM Institut Carnot, and is also Head of early trials of the European Mantle Cell Lymphoma study group. Dr Ribrag’s strong expertise in both early clinical development of innovative therapies and translational cancer research makes in a strong asset for PEGASCY.

Dr. Debussche brings over 35 years of experience in oncology R&D, holding senior leadership roles at major pharmaceutical companies. Most recently, he served as VP Global Head of Oncology Research at Sanofi, where he advanced several first-in-human oncology drug candidates, utilizing a wide range of technologies, including small molecules, monoclonal antibodies (MAbs), nanobodies, antibody-drug conjugates (ADCs), cell engagers, and more. His expertise spans strategic management of preclinical research and clinical trials, leading to the successful development of novel cancer therapies.

He has co-authored over 60 international scientific publications, holds several dozen patents and has a broad industrial and academic networks. With a PhD in Molecular Biology from Pierre et Marie Curie University (France), Laurent has led innovative research initiatives throughout his career, addressing unmet medical needs.

Caroline brings more than 26 years of academic, biotech and industry experience. After Servier and Gencell/Serono, Caroline joined Centelion, a legacy company from sanofi, in January 2003 as a Project Director, and moved to Sanofi Regulatory Affairs group in December 2004 where she held multiple roles of increasing responsibilities in Regulatory Development & Transformation over the course of the last 18 years up to VP in charge of Global Regulatory Affairs for Europe. She was also serving as the R&D representative at Sanofi-Aventis Deutschland GmBH & Hoechst GmBH Board of Directors.
A passionate advocate for purpose-driven leadership, she is recognized for her work leading regulatory teams to innovate in their ways of working and developing best-in-class industry capabilities. With a solid track record for her focus on people development, she developed a strong pipeline of leaders for the organization and retained key talent within Sanofi.
Initially graduated as an engineer in Biochemistry, Biology and Nutraceutical at the National Institute of Agronomy in France, she completed her scientific education at the Pasteur Institute with a Ph.D. and a post-doctoral fellowship in Cardio-vascular gene therapy. She holds a Degree in Bio-medical and Genetic studies from Gustave Roussy Institute and was graduated in 2022 with an Executive MBA at Ecole Polytechnique with a major in Technology & management of Innovation and is currently completing a Board Certification at IFA-Sciences Po.